Literature DB >> 17182012

Immunohistochemical localization of dopamine receptor subtypes (D1R-D5R) in Alzheimer's disease brain.

Ujendra Kumar1, Shutish C Patel.   

Abstract

Among the neurotransmitter abnormalities that have been investigated in Alzheimer's disease (AD), deficits in the cholinergic system have been the most intensively studied. Another key neurotransmitter system involved with emotion and cognition is the dopaminergic system. Here we have investigated alterations in all five dopamine receptor subtypes in AD brain. Using antipeptide rabbit antibodies for each of the five dopamine receptors (D1-D5) we mapped the distribution of these receptors in postmortem AD and age-matched control brains in the frontal cortex, utilizing biotin-avidin immunocytochemistry. All five DR subtypes were expressed as cell surface and cytoplasmic proteins. Receptor-specific changes in control and AD brain were identified as follows: D4R and D3R were the predominant receptor subtypes in age-matched controls followed by D2R and D1R; D5R is the least expressed receptor subtype. In AD brain, D2R and D5R are well expressed in comparison to D1R, D3R and D4R. Expression of D1R, D3R and D4R was severely reduced in AD cortex. D2R expression is moderately reduced in the frontal cortex of AD brain. D5R is the only receptor subtype whose expression is increased in AD frontal cortex. Furthermore, in AD, we found comparable expression of D3R in astrocytes, whereas D5R-like immunoreactivity is significantly increased in astrocytes, in comparison to normal frontal cortex, where it was predominantly neuronal. These results demonstrate subtype-specific changes in dopamine receptors in AD that may be important in disease pathophysiology and that may also serve as potential targets for therapeutic intervention in AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17182012     DOI: 10.1016/j.brainres.2006.10.049

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  32 in total

Review 1.  CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.

Authors:  Alessandro Stefani; Livia Brusa; Enrica Olivola; Mariangela Pierantozzi; Alessandro Martorana
Journal:  J Neural Transm (Vienna)       Date:  2012-05-24       Impact factor: 3.575

2.  Paxillin and hydrogen peroxide-inducible clone 5 expression and distribution in control and Alzheimer disease hippocampi.

Authors:  John Caltagarone; Ronald L Hamilton; Geoffrey Murdoch; Zheng Jing; Donald B DeFranco; Robert Bowser
Journal:  J Neuropathol Exp Neurol       Date:  2010-04       Impact factor: 3.685

Review 3.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

4.  Expression and distribution of all dopamine receptor subtypes (D(1)-D(5)) in the mouse lumbar spinal cord: a real-time polymerase chain reaction and non-autoradiographic in situ hybridization study.

Authors:  H Zhu; S Clemens; M Sawchuk; S Hochman
Journal:  Neuroscience       Date:  2007-09-12       Impact factor: 3.590

5.  Dopaminergic modulation of cortical plasticity in Alzheimer's disease patients.

Authors:  Giacomo Koch; Francesco Di Lorenzo; Sonia Bonnì; Viola Giacobbe; Marco Bozzali; Carlo Caltagirone; Alessandro Martorana
Journal:  Neuropsychopharmacology       Date:  2014-05-26       Impact factor: 7.853

6.  L-dopa modulates motor cortex excitability in Alzheimer's disease patients.

Authors:  Alessandro Martorana; Alessandro Stefani; Maria Giuseppina Palmieri; Zaira Esposito; Giorgio Bernardi; Giuseppe Sancesario; Mariangela Pierantozzi
Journal:  J Neural Transm (Vienna)       Date:  2008-07-02       Impact factor: 3.575

7.  Quantification of D1 and D5 dopamine receptor localization in layers I, III, and V of Macaca mulatta prefrontal cortical area 9: coexpression in dendritic spines and axon terminals.

Authors:  Jill R Bordelon-Glausier; Zafar U Khan; E Chris Muly
Journal:  J Comp Neurol       Date:  2008-06-20       Impact factor: 3.215

Review 8.  Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease.

Authors:  Riqiang Yan; Qingyuan Fan; John Zhou; Robert Vassar
Journal:  Neurosci Biobehav Rev       Date:  2016-04-01       Impact factor: 8.989

Review 9.  The impact of substance abuse on HIV-mediated neuropathogenesis in the current ART era.

Authors:  Vanessa Chilunda; Tina M Calderon; Pablo Martinez-Aguado; Joan W Berman
Journal:  Brain Res       Date:  2019-08-29       Impact factor: 3.252

Review 10.  Volume Transmission in Central Dopamine and Noradrenaline Neurons and Its Astroglial Targets.

Authors:  Kjell Fuxe; Luigi F Agnati; Manuela Marcoli; Dasiel O Borroto-Escuela
Journal:  Neurochem Res       Date:  2015-04-17       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.